Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to test the effectiveness, safety and tolerability of the drug combination: gemcitabine, carboplatin and bevacizumab in patients that have been diagnosed with platinum sensitive recurrent ovarian cancer, fallopian tube or primary peritoneal cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ohio State University Comprehensive Cancer Center
• Collaborators: Eli Lilly and Company; Genentech, Inc.
• Treatments: Bevacizumab; Carboplatin; Gemcitabine

Criteria

Inclusion Criteria:

• Cancer of the ovaries, fallopian tube or abdominal lining has come back after more than 6 months from the last platinum based chemotherapy treatment.

• Disease must be detected by CT or CA125 level must be elevated or cancerous ascites must be present.

• History of at least one therapy of platinum based chemotherapy.

Exclusion Criteria:

• Participation in another experimental drug study

• Heart disease or high blood pressure

• History of a stroke within the past 6 months

• Vascular disease, or bleeding problems

• Brain cancer

• Major Surgical Procedure within 28 days prior to start date

• Minor surgical procedures within 7 days prior to start date

• Pregnant or lactating

• Abdominal or bowel problems like bleeding

• History of abdominal fistula, GI perforation or Intra-abdominal abscess

• Serious, non-healing wound, ulcer or bone fracture

• Acute hepatitis

• Active infections requiring antibiotics

• Inability to comply with study or follow up procedures